Genetic testing has forayed into various therapeutic areas and it is starting to influence the field of oncology in a big way. “Roche’s acquisition of Foundation Medicine and its vision for personalized medicine shares its origin in the realization that in the last hundred years anatomical and histological classification of tumors is going through paradigm shift toward a pan tumor molecular classification. It is now clear that cancer originates from an accumulation of genetic alterations over a period of time and it is important to identify targetable driver mutations” says Dr. Nicolas Martin, International Scientific Lead at Roche Foundation Medicine. He firmly believes that comprehensive genomic profiling is the future and it definitely outperforms existing technologies.